Seeing Is Believing
Currently out of the existing stock ratings of Josh Schimmer, 142 are a BUY (87.12%), 19 are a HOLD (11.66%), 2 are a SELL (1.23%).
Analyst Josh Schimmer, currently employed at EVERCORE, carries an average stock price target met ratio of 50.51% that have a potential upside of 46.93% achieved within 288 days.
Josh Schimmer’s has documented 656 price targets and ratings displayed on 36 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ASND, Ascendis Pharma AS at 02-May-2025.
Analyst best performing recommendations are on INSM (INSMED).
The best stock recommendation documented was for INSM (INSMED) at 8/16/2017. The price target of $28 was fulfilled within 21 days with a profit of $16.29 (139.11%) receiving and performance score of 66.24.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$205
$22.5 (12.33%)
4 years 1 months 17 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold
$173
$-9.5 (-5.21%)
$156
4 years 1 months 19 days ago
(03-May-2021)
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
$190
4 years 1 months 27 days ago
(26-Apr-2021)
9/11 (81.82%)
$34.41 (22.12%)
350
Hold
$166
$-16.5 (-9.04%)
$175
4 years 4 months 18 days ago
(04-Feb-2021)
23/23 (100%)
$10.41 (6.69%)
828
Buy
$155
4 years 5 months 15 days ago
(07-Jan-2021)
7/7 (100%)
$36.79 (31.12%)
395
Which stock is Josh Schimmer is most bullish on?
Which stock is Josh Schimmer is most reserved on?
What Year was the first public recommendation made by Josh Schimmer?